Prediction of human serum concentration–time profiles of therapeutic monoclonal antibodies using common marmosets ( <i>Callithrix jacchus</i> ): initial assessment with canakinumab, adalimumab, and bevacizumab-Reference-Cited by-同舟云学术

Prediction of human serum concentration–time profiles of therapeutic monoclonal antibodies using common marmosets ( Callithrix jacchus ): initial assessment with canakinumab, adalimumab, and bevacizumab

Published:2024-07-26 Issue: Volume: Page:1-10
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Tajiri Ayaka¹^ORCID,Matsumoto Shogo¹^ORCID,Maeda Satoshi²,Soga Takuma²^ORCID,Kagiyama Kensuke²,Ikeda Hiroshi³,Fukasawa Kazumasa²,Miyata Atsunori¹,Kamimura Hidetaka⁴^ORCID

Affiliation:

1. Drug Discovery Department, R&D Division, Meiji Seika Pharma Co., Ltd, Tokyo, Japan

2. Yaotsu Breeding Center, CLEA Japan, Inc., Gifu, Japan

3. Tokyo Animal and Diet Department, CLEA Japan, Inc., Tokyo, Japan

4. Business Promotion Department, CLEA Japan, Inc., Tokyo, Japan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2024.2371921

Reference45 articles.

1. Adalimumab (Humira) New Drug Application (NDA). PMDA (Pharmaceuticals and Medical Devices Agency) (Japanese). www.pmda.go.jp/drugs/2008/P200800019/index.html.

2. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

3. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach

4. Bevacizumab (Avastin) New Drug Application (NDA): Available at the website of PMDA (Pharmaceuticals and Medical Devices Agency) (Japanese). www.pmda.go.jp/drugs/2007/P200700027/index.html.

5. Prevention of Experimental Autoimmune Encephalomyelitis in the Common Marmoset (Callithrix jacchus) Using a Chimeric Antagonist Monoclonal Antibody Against Human CD40 Is Associated with Altered B Cell Responses